Since that time, Biogen released results for the first quarter, where they came in above their bottom line consensus. The company also made the following guidance:
- Revenues are expected to grow at a rate of high single digits compared to 2008
- Operating expenses are expected to total $2.0 to $2.1 billion
- R&D is expected to be 26-28% of revenues, with SG&A at 19-20% of revenues
- The effective non-GAAP tax rate is expected to be approximately 28-30%
- Adjusted EPS is expected to be at or above $4.00
- GAAP EPS is expected to be at or above $2.80
No comments:
Post a Comment